Tetraphase Pharmaceuticals of Watertown, MA, announced today that it has raised a $15 million second tranche of its $25 million Series A financing. The cash comes from Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures, and Skyline Ventures, who backed the startup when it spun out of Harvard in 2006 to develop synthetic antibiotics, as we explained in a profile of Tetraphase last fall.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
